JPRN-UMIN000011713招募中2 期
A phase II study of Bevacizumab plus Docetaxel for advanced large cell neuroendocrine carcinoma (LCNEC) with previously treated with platinum based chemotherapy - A phase II study of Bevacizumab plus Docetaxel for advanced large cell neuroendocrine carcinoma (LCNEC) with previously treated with platinum based chemotherapy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 19
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Severe or uncontrollable systemic disease 2) Active infection 3) Active concomitant malignancy 4) Symptomatic brain metastasis 5) Uncontrollable pleural effusion, ascites, or pericardial effusion 6) History of GI perforation 7) Tendency to hemorrhages 8) Pregnancy, breast feeding and suspected pregnancy 9) Invasion to major vessel or cavitations of tumor 10) Uncontrollable hypertension 11) Inappropriate patients for this study judged by the physicians
研究者
相似试验
招募中
2 期
A phase II study of Bevacizumab and Docetaxel for elderly patients advanced Non-Small Cell Lung Canceron-squamous non-small cell lung cancerJPRN-UMIN000006322niversity hospital, Hirosaki University School of Medicine Cardiology,respiratory medicine and nephrology30
已完成
2 期
A phase II study of Docetaxel with Bevacizumab for EGFR mutation negative previously treated non-squamous non-small cell lung canceron-Squamous Non-Small Cell Lung CancerJPRN-UMIN000006532ihon University School of Medicine30
已完成
不适用
A phase II study of Docetaxel with Bevacizumab for previously treated non-squamous non-small cell lung cancer.non-squamous non-small cell lung cancer.JPRN-UMIN000008687First Department of Internal Medicine,25
已完成
1 期
Phase I/II study of Docetaxel with Bevacizumab for refractory and geriatric non-squamous non-small cell lung canceron-Squamous Non-Small Cell Lung CancerJPRN-UMIN000006152Chiba Tokushukai Hospital20
进行中（未招募）
不适用
A phase II study of Bevacizumab with Docetaxel and Capecitabine in the neoadjuvant setting for breast cancer patientsneoadjuvant treatment of patients with primary breast cancer and no distant metastasesEUCTR2005-005883-10-ATRoche Austria GmbH10